Indeed, the addition of a CD47-specific blocking mAb to gefitinib-treated or untreated HCC827 and H1975 cells significantly increased the percentage of DiO-positive dendritic cells, while addition of an isotype control did not affect tumor cell engulfment (Figures 5A,B). This evidence concerns the gene CD47 and neoplasm.